Naki Therapeutics
Pharmaceuticals - Summit, New Jersey, United States
Naki Therapeutics Employees
Naki Therapeutics Details
Our core technology is surrounding Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy with ground-breaking allogeneic or ‘off-the-shelf' expansion technology and a ‘first-in-class' solid tumor molecular target-CD147.Our approach is to re-engineer NK cells-which belong to the human innate immune system to target the specific cancer cell surface marker CD147, and thereby kill the cancer cells more effectively and safely in comparison to existing treatments.To deliver this therapy cost-effectively and in a scalable way, we also have developed proprietary methods to expand ‘memory-like', highly potent, ‘off-the-shelf' NK and CAR-NK cells fast and with high purity. Our initial indication is hepatocellular carcinoma (HCC), a devastating solid tumor with marginally effective standard of care.
Naki Therapeutics Technologies
Email Providers
Outlook
Load Balancers
Apache
CMS
WordPress.org
Fonts
Google Font API
Hosting
GoDaddy Hosting
Other
Mobile Friendly